AG

Ascenion GmbH

Europe, Bayern, Germany, Munich

Description

Ascenion GmbH is a biotechnology company that also manufactures pharmaceuticals.

Investor Profile

Ascenion GmbH has made 3 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series B (67%)
  • Series A (33%)

Country Focus

  • Germany (100%)

Industry Focus

  • Health Care
  • Therapeutics
  • Artificial Intelligence (Ai)
  • Health Diagnostics
  • Machine Learning
  • Software
  • Biotechnology
  • Life Science
  • Medical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Ascenion GmbH frequently co-invest with?

Wellington Partners
Europe, Bayern, Germany, Munich
Co-Investments: 1
Boehringer Ingelheim Venture Fund
Europe, Rheinland-Pfalz, Germany, Ingelheim Am Rhein
Co-Investments: 2
KfW
Europe, Hessen, Germany, Frankfurt
Co-Investments: 1
SMS Group
Europe, Nordrhein-Westfalen, Germany, Düsseldorf
Co-Investments: 1
HTGF | High-Tech Gruenderfonds
Europe, Nordrhein-Westfalen, Germany, Bonn
Co-Investments: 2
Co-Investments: 1
Novo Holdings
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 1
VF
Europe, Berlin, Germany, Berlin
Co-Investments: 1
coparion
Europe, Nordrhein-Westfalen, Germany, Cologne
Co-Investments: 1
IBB Ventures
Europe, Berlin, Germany, Berlin
Co-Investments: 1

What are some of recent deals done by Ascenion GmbH?

Aignostics

Berlin, Berlin, Germany

Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research.

Artificial Intelligence (AI)Health CareHealth DiagnosticsMachine LearningSoftware
Series ASep 15, 2022
Amount Raised: $13,982,494
HepaRegeniX

Ulm, Baden-Wurttemberg, Germany

HepaRegeniX is developing drugs for treating acute and chronic liver diseases.

BiotechnologyHealth CareLife ScienceTherapeutics
Series BJan 21, 2020
Amount Raised: $12,193,648
OMEICOS Therapeutics

Berlin, Berlin, Germany

OMEICOS Therapeutics is developing a novell molecule utilizing a new Mode of Action for the treatment and prevention of atrial fibrillation.

Health CareMedicalTherapeutics
Series BMar 1, 2017
Amount Raised: $8,744,832